December 18, 2024
Advised by Nordea Corporate Finance, B2B pharmaceuticals distributor ApoEx is working on a potential carve-out of its Non-prescription Business with NBOs due before Christmas acc. to sources - Marketed off annual revenues of SEK ~650m (NKP | M&A Insights Proprietary)
NKP | M&A Insights Proprietary
Headline from pre-deal coverage in M&A Insights